Drug Trial Radar · NCT06556173
Phase 2a Study of VTX3232 in Parkinson's Disease
Last checked: Nov 19, 2026Latest source record: Apr 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
11
Actual
Start
Aug 8, 2024
Primary completion
Apr 4, 2025
Study completion Apr 4, 2025
Sponsor
- Lead sponsor
- Zomagen Biosciences Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 15, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study to understand if taking VTX3232 is safe in participants diagnosed with early stage idiopathic Parkinson's Disease (PD). Approximately 10 patients will take VTX3232 Dose A. The study consists of a 30-day Screening Period (to see if a participant qualifies for the study), a 7-day Pre-Baseline Period, a 28-day Open Label Treatment period (a participant receives active Dose A), and a 14-day Follow-Up Period.
Conditions
- Idiopathic Parkinson Disease
Interventions
VTX3232Drug
Dose A
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse Event (AE) / Serious Adverse Event (SAE) Incidence Rate and Severity through study completionTime frame: Day 1 of treatment period through study completion, up to 6 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Local Site #840001
New Haven, Connecticut
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.